Cover
Cover - shares | 3 Months Ended | |
Nov. 30, 2023 | Jan. 22, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Nov. 30, 2023 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2024 | |
Current Fiscal Year End Date | --08-31 | |
Entity File Number | 001-40089 | |
Entity Registrant Name | Novo Integrated Sciences, Inc. | |
Entity Central Index Key | 0001138978 | |
Entity Tax Identification Number | 59-3691650 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | 11120 NE 2nd Street | |
Entity Address, Address Line Two | Suite 100 | |
Entity Address, City or Town | Bellevue | |
Entity Address, State or Province | WA | |
Entity Address, Postal Zip Code | 98004 | |
City Area Code | (206) | |
Local Phone Number | 617-9797 | |
Title of 12(b) Security | Common Stock | |
Trading Symbol | NVOS | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 17,748,320 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Current Assets: | ||
Cash and cash equivalents | $ 1,640,007 | $ 416,323 |
Accounts receivable, net | 2,636,174 | 1,467,028 |
Inventory, net | 1,270,835 | 1,106,983 |
Other receivables | 1,047,742 | 1,051,584 |
Prepaid expenses and other current assets | 213,812 | 346,171 |
Total current assets | 6,808,570 | 4,388,089 |
Property and equipment, net | 5,306,613 | 5,390,038 |
Intangible assets, net | 15,704,218 | 16,218,539 |
Right-of-use assets, net | 1,870,204 | 1,983,898 |
Goodwill | 7,554,779 | 7,582,483 |
TOTAL ASSETS | 37,244,384 | 35,563,047 |
Current Liabilities: | ||
Accounts payable | 3,403,634 | 3,513,842 |
Accrued expenses | 1,300,549 | 1,233,549 |
Accrued interest (including amounts to related parties) | 480,719 | 382,666 |
Government loans and notes payable, current portion | 93,488 | 277,405 |
Convertible notes payable, net of discount of $3,118,819 | 1,103,959 | 558,668 |
Derivative liability | 2,686,260 | |
Contingent liability | 52,749 | 61,767 |
Debentures, related parties | 913,474 | 916,824 |
Finance lease liability | 8,907 | 11,744 |
Operating lease liability, current portion | 413,506 | 415,392 |
Total current liabilities | 10,915,511 | 7,904,858 |
Government loans and notes payable, net of current portion | 63,777 | 65,038 |
Operating lease liability, net of current portion | 1,585,667 | 1,693,577 |
Deferred tax liability | 1,395,381 | 1,400,499 |
TOTAL LIABILITIES | 13,960,336 | 11,063,972 |
Commitments and contingencies | ||
Novo Integrated Sciences, Inc. | ||
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at November 30, 2023 and August 31, 2023, respectively | ||
Common stock; $0.001 par value; 499,000,000 shares authorized; 17,291,192 and 15,759,325 shares issued and outstanding at November 30, 2023 and August 31, 2023, respectively | 17,292 | 15,760 |
Additional paid-in capital | 95,481,354 | 90,973,316 |
Common stock to be issued (17,375 and 91,138 shares at November 30, 2023 and August 31, 2023) | 44,443 | 1,217,293 |
Other comprehensive loss | (246,488) | (357,383) |
Accumulated deficit | (71,713,384) | (67,033,041) |
Total Novo Integrated Sciences, Inc. stockholders’ equity | 23,583,217 | 24,815,945 |
Noncontrolling interest | (299,169) | (316,870) |
Total stockholders’ equity | 23,284,048 | 24,499,075 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 37,244,384 | 35,563,047 |
Related Party [Member] | ||
Current Liabilities: | ||
Due to related parties | $ 458,266 | $ 533,001 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Statement of Financial Position [Abstract] | ||
Convertible notes payable net of discount current | $ 3,118,819 | $ 3,118,819 |
Convertible preferred stock, par value | $ 0.001 | $ 0.001 |
Convertible preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Convertible preferred stock, shares issued | 0 | 0 |
Convertible preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 499,000,000 | 499,000,000 |
Common stock, shares issued | 17,291,192 | 15,759,325 |
Common stock, shares outstanding | 17,291,192 | 15,759,325 |
Common stock to be issued, shares | 17,375 | 91,138 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | |
Nov. 30, 2023 | Nov. 30, 2022 | |
Income Statement [Abstract] | ||
Revenues | $ 3,891,218 | $ 3,419,280 |
Cost of revenues | 1,947,200 | 1,679,747 |
Gross profit | 1,944,018 | 1,739,533 |
Operating expenses: | ||
Selling expenses | 9,586 | 7,332 |
General and administrative expenses | 5,252,069 | 3,974,161 |
Total operating expenses | 5,261,655 | 3,981,493 |
Loss from operations | (3,317,637) | (2,241,960) |
Non-operating income (expense) | ||
Interest income | 2,219 | 2,281 |
Interest expense | (143,374) | (167,243) |
Other expense | (652,174) | |
Change in fair value of derivative liability | 585,529 | |
Amortization of debt discount | (1,075,928) | (1,490,513) |
Foreign currency transaction losses | (59,358) | (39,301) |
Total non-operating expense | (1,343,086) | (1,694,776) |
Loss before income taxes | (4,660,723) | (3,936,736) |
Income tax expense | ||
Net loss | (4,660,723) | (3,936,736) |
Net income (loss) attributed to noncontrolling interest | 19,620 | (1,323) |
Net loss attributed to Novo Integrated Sciences, Inc. | (4,680,343) | (3,935,413) |
Comprehensive loss: | ||
Net loss | (4,660,723) | (3,936,736) |
Foreign currency translation gain (loss) | 108,976 | (420,982) |
Comprehensive loss: | $ (4,551,747) | $ (4,357,718) |
Weighted average common shares outstanding - basic | 16,726,308 | 3,385,508 |
Weighted average common shares outstanding - diluted | 16,726,308 | 3,385,508 |
Net loss per common share - basic | $ (0.28) | $ (1.16) |
Net loss per common share - diluted | $ (0.28) | $ (1.16) |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Common Stock To Be Issued [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total Novo Stockholders Equity [Member] | Noncontrolling Interest [Member] | Total |
Balance at Aug. 31, 2022 | $ 3,118 | $ 66,084,887 | $ 9,474,807 | $ 560,836 | $ (53,818,489) | $ 22,305,159 | $ (257,588) | $ 22,047,571 |
Balance, shares at Aug. 31, 2022 | 3,118,063 | |||||||
Cashless exercise of warrants | $ 467 | $ 1,138,583 | $ 1,139,050 | $ 1,139,050 | ||||
Cashless exercise of warrants, shares | 467,399 | |||||||
Issuance of common stock to be issued | 4 | 92,362 | (92,366) | |||||
Issuance of common stock to be issued, shares | 3,623 | |||||||
Foreign currency translation loss | $ (417,008) | $ (417,008) | $ (3,974) | $ (420,982) | ||||
Net Income (loss) | (3,935,413) | (3,935,413) | (1,323) | (3,936,736) | ||||
Units issued for cash, net of offering costs | $ 400 | 1,794,600 | 1,795,000 | 1,795,000 | ||||
Units issued for cash, net of offering costs, shares | 400,000 | |||||||
Fair value of stock options | 60,887 | 60,887 | 60,887 | |||||
Balance at Nov. 30, 2022 | $ 3,989 | 69,171,319 | 9,382,441 | 143,828 | (57,753,902) | 20,947,675 | (262,885) | 20,684,790 |
Balance, shares at Nov. 30, 2022 | 3,989,085 | |||||||
Balance at Aug. 31, 2023 | $ 15,760 | 90,973,316 | 1,217,293 | (357,383) | (67,033,041) | 24,815,945 | (316,870) | 24,499,075 |
Balance, shares at Aug. 31, 2023 | 15,759,325 | |||||||
Cashless exercise of warrants | $ 246 | 1,323,152 | 1,323,398 | 1,323,398 | ||||
Cashless exercise of warrants, shares | 245,802 | |||||||
Exercise of warrants for cash | $ 240 | 240,160 | 240,400 | 240,400 | ||||
Exercise of warrants for cash, shares | 240,400 | |||||||
Share issuance for convertible debt settlement | $ 520 | $ 577,002 | $ 577,522 | $ 577,522 | ||||
Share issuance for convertible debt settlement, shares | 519,845 | |||||||
Issuance of common stock to be issued | 74 | 1,172,776 | (1,172,850) | |||||
Issuance of common stock to be issued, shares | 73,767 | |||||||
Common stock issued for services | $ 424 | $ 1,194,976 | $ 1,195,400 | $ 1,195,400 | ||||
Common stock issued for services, shares | 424,080 | |||||||
Rounding due to stock split | $ 28 | (28) | ||||||
Rounding due to stock split | 27,973 | |||||||
Foreign currency translation loss | 110,895 | 110,895 | (1,919) | 108,976 | ||||
Net Income (loss) | (4,680,343) | (4,680,343) | 19,620 | (4,660,723) | ||||
Balance at Nov. 30, 2023 | $ 17,292 | $ 95,481,354 | $ 44,443 | $ (246,488) | $ (71,713,384) | $ 23,583,217 | $ (299,169) | $ 23,284,048 |
Balance, shares at Nov. 30, 2023 | 17,291,192 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 12 Months Ended | |
Nov. 30, 2023 | Nov. 30, 2022 | Aug. 31, 2023 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||
Net loss | $ (4,660,723) | $ (3,936,736) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 572,404 | 586,166 | |
Fair value of vested stock options | 60,887 | ||
Financing costs for debt extension | 1,323,398 | 1,139,050 | |
Common stock issued for services | 1,195,400 | ||
Operating lease expense | 149,877 | 209,846 | |
Amortization of debt discount | 1,075,928 | 1,490,513 | |
Foreign currency transaction losses | 59,358 | 39,301 | |
Change in fair value of derivative liability | (585,529) | ||
Changes in operating assets and liabilities: | |||
Accounts receivable | (1,168,350) | 28,174 | |
Inventory | (166,476) | (157,118) | |
Prepaid expenses and other current assets | 130,584 | 1,471 | |
Accounts payable | (98,996) | 321,961 | |
Accrued expenses | 71,214 | 149,945 | |
Accrued interest | 99,430 | (9,232) | |
Operating lease liability | (149,877) | (202,465) | |
Net cash used in operating activities | (2,152,358) | (278,237) | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Repayments to related parties | (72,402) | (48,480) | |
Repayments of notes payable | (183,100) | ||
Repayments of finance leases | (2,779) | (2,763) | |
Proceeds from issuance of convertible notes | 3,314,153 | ||
Repayment of convertible notes | (2,777,778) | ||
Proceeds from the sale of units, net of offering costs | 1,795,000 | ||
Proceeds from exercise of warrants | 240,400 | ||
Net cash provided by (used in) financing activities | 3,296,272 | (1,034,021) | |
Effect of exchange rate changes on cash and cash equivalents | 79,770 | 12,271 | |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 1,223,684 | (1,299,987) | |
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 416,323 | 2,178,687 | $ 2,178,687 |
CASH AND CASH EQUIVALENTS, END OF PERIOD | 1,640,007 | 878,700 | $ 416,323 |
CASH PAID FOR: | |||
Interest | 45,321 | 186,911 | |
Income taxes | |||
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES: | |||
Debt discount recognized on derivative liability | 3,071,653 | 1,390,380 | |
Common stock issued for convertible debt settlement | 577,522 | ||
Debt discount recognized on convertible note | $ 3,735,414 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) | 3 Months Ended | |
Nov. 30, 2023 | Nov. 30, 2022 | |
Pay vs Performance Disclosure [Table] | ||
Net Income (Loss) Attributable to Parent | $ (4,680,343) | $ (3,935,413) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Nov. 30, 2023 | |
Insider Trading Arrangements [Line Items] | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Organization and Basis of Prese
Organization and Basis of Presentation | 3 Months Ended |
Nov. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Basis of Presentation | Note 1 - Organization and Basis of Presentation Organization and Line of Business Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries. The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, unique personalized product offerings, and rehabilitative science. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: ● First Pillar – Service Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. ● Second Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home. ● Third Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) Novo Healthnet Limited (“NHL”), (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 1,677,974 85 On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, and not as a business combination, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $ 6,904 Reverse Stock Split On November 7, 2023, the Company effected a 1-for-10 reverse stock split 1-for-10 reverse stock split Basis of Presentation The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations. The financial information contained in this report should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended August 31, 2023, that the Company filed on December 14, 2023. The results of operations for the three months ended November 30, 2023 are not necessarily indicative of the results for the fiscal year ending August 31, 2024. The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”) and the parent company’s functional currency is the United States Dollar (“$” or “USD”); however, the accompanying unaudited condensed consolidated financial statements were translated and presented in USD. Going Concern The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. The Company has incurred recurring losses from operations, has negative cash flows from operating activities, and has an accumulated deficit as of November 30, 2023. The Company believes that its cash and other available resources may not be sufficient to meet its operating needs and the payment of obligations related to various business acquisitions as they come due within one year after the date the unaudited condensed consolidated financial statements are issued. In an effort to alleviate these conditions, the Company has considered equity and/or debt financing and/or asset monetization. There can be no assurance that funding would be available, or that the terms of such funding would be on favorable terms if available. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing. These conditions, along with the matters noted above, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. While management has developed and is in process to implement plans that management believes could alleviate in the future the substantial doubt that was raised, management concluded at the date of the issuance of the unaudited condensed consolidated financial statements that substantial doubt exists as those plans are not completely within the control of management. These unaudited condensed consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and consolidated balance sheets classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material. Foreign Currency Translation The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction Comprehensive Income Schedule of Foreign Currency Translation, Exchange Rate Used November 30, 2023 November 30, 2022 August 31, 2023 Period end: CAD to USD exchange rate $ 0.7363 $ 0.7403 $ 0.7390 Average period: CAD to USD exchange rate $ 0.7324 $ 0.7414 $ 0.7426 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Nov. 30, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, valuation of derivative liability, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls, including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss. Cash Equivalents For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of November 30, 2023 and August 31, 2023, the allowance for uncollectible accounts receivable was $ 855,116 864,215 Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of November 30, 2023 and August 31, 2023, the Company’s allowance for slow moving or obsolete inventory was $ nil nil Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the three months ended November 30, 2023 and year ended August 31, 2023, the Company wrote off $ nil nil Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5 Leases The Company applies the provisions of ASC Topic 842, Leases Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment no Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its review at November 30, 2023, the Company believes there was no Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. Based on its review at November 30, 2023, the Company believes there was no Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Beginning balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Foreign currency translation adjustment (675 ) (443 ) (783 ) (25,801 ) (2 ) (27,704 ) Balance, November 30, 2023 $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 Ending balance $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of November 30, 2023 and August 31, 2023, respectively, the Company did not identify any financial assets and liabilities required to be presented on the condensed consolidated balance sheet at fair value, except for contingent liability which is carried at fair value using Level 1 inputs and derivative liability which is carried at fair value using Level 3 inputs. Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives. Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery. In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying condensed consolidated balance sheets. Sales returns and allowances were insignificant for the three months ended November 30, 2023 and 2022. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 659,616 1,860,950 3,786,454 17,375 Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented. Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gain of $ 108,976 922,609 Condensed Consolidated Statements of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the condensed consolidated balance sheets. Segment Reporting ASC Topic 280, Segment Reporting two Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying condensed consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances. |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Nov. 30, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 3 – Related Party Transactions Due to related parties Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At November 30, 2023 and August 31, 2023, the amount due to related parties was $ 458,266 533,001 376,701 nil 6 81,565 13.75 451,137 21,267 6 60,597 13.75 |
Accounts Receivables, Net
Accounts Receivables, Net | 3 Months Ended |
Nov. 30, 2023 | |
Receivables [Abstract] | |
Accounts Receivables, Net | Note 4 – Accounts Receivables, Net Accounts receivables, net at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Accounts Receivable, Net November 30, August 31, 2023 2023 Trade receivables $ 3,412,783 $ 2,223,243 Amounts earned but not billed 78,507 108,000 Accounts receivables gross 3,491,290 2,331,243 Allowance for doubtful accounts (855,116 ) (864,215 ) Accounts receivable, net $ 2,636,174 $ 1,467,028 |
Inventory
Inventory | 3 Months Ended |
Nov. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Inventory | Note 5 – Inventory Inventory at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Inventory November 30, August 31, 2023 2023 Raw materials $ 516,811 $ 388,391 Work in process 108,244 81,696 Finished Goods 645,780 636,896 Inventory Gross 1,270,835 1,106,983 Allowance for slow moving and obsolete inventory - - Inventory, net $ 1,270,835 $ 1,106,983 |
Other Receivables
Other Receivables | 3 Months Ended |
Nov. 30, 2023 | |
Receivables [Abstract] | |
Other Receivables | Note 6 – Other Receivables Other receivables at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Other Receivables November 30, August 31, Advance to corporation; accrues interest at 12 January 31, 2024 $ 73,630 $ 73,900 Advance to corporation; accrues interest at 12 February 1, 2024 532,433 534,386 Advance to corporation; accrues interest at 10 February 1, 2024 441,679 443,298 Total other receivables 1,047,742 1,051,584 Current portion (1,047,742 ) (1,051,584 ) Long-term portion $ - $ - |
Property and Equipment
Property and Equipment | 3 Months Ended |
Nov. 30, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | Note 7 – Property and Equipment Property and equipment at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Property and Equipment November 30, August 31, 2023 2023 Land $ 441,780 $ 443,400 Building 3,313,350 3,325,500 Leasehold improvements 838,297 841,371 Clinical equipment 1,909,678 1,916,681 Computer equipment 33,381 33,504 Office equipment 44,400 44,502 Furniture and fixtures 38,149 38,289 Property and Equipment gross 6,619,035 6,643,247 Accumulated depreciation (1,312,422 ) (1,253,209 ) Total $ 5,306,613 $ 5,390,038 Depreciation expense for the three months ended November 30, 2023 and 2022 was $ 72,604 60,043 Certain property and equipment have been used to secure notes payable (See Note 10). |
Intangible Assets
Intangible Assets | 3 Months Ended |
Nov. 30, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Note 8 – Intangible Assets Intangible assets at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Intangible Assets November 30, August 31, 2023 2023 Land use rights $ 11,573,321 $ 11,573,321 Intellectual property 7,487,410 7,497,746 Customer relationships 2,287,746 2,291,058 Brand names 1,921,375 1,928,421 Finite lived intangible assets, gross 23,269,852 23,290,546 Accumulated amortization (7,565,634 ) (7,072,007 ) Total $ 15,704,218 $ 16,218,539 Amortization expense for the three months ended November 30, 2023 and 2022 was $ 499,800 526,123 Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of intangible Assets Twelve Months Ending November 30, 2024 $ 2,003,586 2025 1,820,324 2026 1,454,624 2027 1,208,004 2028 639,025 Thereafter 8,578,655 Total $ 15,704,218 |
Accrued Expenses
Accrued Expenses | 3 Months Ended |
Nov. 30, 2023 | |
Payables and Accruals [Abstract] | |
Accrued Expenses | Note 9 – Accrued Expenses Accrued expenses at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Accrued Expenses November 30, August 31, 2023 2023 Accrued liabilities $ 1,049,543 $ 961,897 Accrued payroll 215,936 236,218 Unearned revenue 35,070 35,434 Accrued expense $ 1,300,549 $ 1,233,549 |
Government Loans and Notes Paya
Government Loans and Notes Payable | 3 Months Ended |
Nov. 30, 2023 | |
Government Loans And Notes Payable | |
Government Loans and Notes Payable | Note 10 – Government Loans and Notes Payable Notes payable at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Governmental Loans and Note Payable November 30, August 31, 2023 2023 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program ( A 88,356 88,680 Note payable to the Small Business Administration. The note bears interest at 3.75 190 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 4,000 December 2, 2028 28,589 28,693 Note payable received May 25, 2023, accruing interest at 18 - 73,900 Note payable received May 10, 2023, accruing interest at 15 - 110,850 Total government loans and notes payable 157,265 342,443 Less current portion (93,488 ) (277,405 ) Long-term portion $ 63,777 $ 65,038 (A) The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 58,904 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,452 Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of government Loans and Notes Payable Twelve Months Ending November 30, 2024 $ 93,488 2025 6,470 2026 6,469 2027 6,469 2028 6,469 Thereafter 37,900 Total $ 157,265 |
Convertible Notes Payable
Convertible Notes Payable | 3 Months Ended |
Nov. 30, 2023 | |
Convertible Notes Payable | |
Convertible Notes Payable | Note 11 – Convertible Notes Payable Novo Integrated On December 14, 2021, Novo Integrated issued two convertible notes payable for a total of $ 16,666,666 8,333,333 5 June 14, 2023 20 In connection with the $16.66m+ convertible notes, the Company issued the note holders warrants to purchase a total of 583,334 20 December 14, 2025 7,680,156 ● Expected life of 4.0 ● Volatility of 275 ● Dividend yield of 0 ● Risk free interest rate of 1.23 The face amount of the $16.66m+ convertible notes of $ 16,666,666 11,409,200 5,257,466 5,257,466 1,666,666 1,140,000 8,064,132 On November 14, 2022, the $16.66m+ convertible notes were amended to provide the holders with conversion rights consisting of a conversion price to the first $ 1,000,000 (i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. derivative liability 1,390,380 ● Expected life of 0.58 ● Volatility of 148.20 ● Dividend yield of 0 ● Risk free interest rate of 4.55 The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible notes. During the year ended August 31, 2023, an aggregate of $ 8,396,666 32,559 8,527,835 1,000,000 1,390,380 nil nil During the year ended August 31, 2023, the Company amortized $ 4,241,429 nil During the year ended August 31, 2023, the Company made cash payments in the aggregate amount of $ 3,001,442 2,833,888 167,554 nil Terragenx On November 17, 2021, Terragenx, a 91 1,875,000 937,500 1 May 17, 2022 33.50 In connection with the $1.875m convertible notes, the Company issued the note holders warrants to purchase a total of 22,388 33.50 The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. 351,240 ● Expected life of 3.0 ● Volatility of 300 ● Dividend yield of 0 ● Risk free interest rate of 0.85 The face amount of the $1.875m convertible notes of $ 1,875,000 1,579,176 295,824 295,824 375,000 90,000 760,824 On June 1, 2022, the Company paid the balance owed on one of two Terragenx $ 1.875 948,874 1.875 192,188 November 29, 2022 937,500 On June 1, 2022, the Company and one of the two Terragenx $ 1.875 November 29, 2022 186,719 Effective February 16, 2023, aside from the Liquidated Damages Charge, the Jefferson Note was paid in full. On August 21, 2023, Jefferson converted the additional Liquidated Damages Charge and the interest thereon. On August 21, 2023, as a result of the conversion, the Company issued 236,511 Novo Integrated – Mast Hill Fund, L.P. On February 23, 2023, the Company entered into a securities purchase agreement (the “Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12 February 23, 2024 573,000 100,000 12 57,300 515,700 1.75 Pursuant to the terms of the Mast Hill Note, the Company agreed to pay accrued interest monthly as well as the Mast Hill Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Mast Hill Note) occurs at an amount equal to the Mast Hill Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any Event of Default, the Mast Hill Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the Mast Hill Principal Sum then outstanding plus accrued interest multiplied by 125 16 The Mast Hill Warrant is exercisable for five years from February 23, 2023, at an exercise price of $ 2.50 86,327 ● Expected life of 5.0 ● Volatility of 252 ● Dividend yield of 0 ● Risk free interest rate of 4.09 As additional consideration for the purchase of the Mast Hill Note and pursuant to the terms of the Mast Hill SPA, on February 24, 2023, the Company issued 95,500 19.99 2,772,045 The principal amount of the $ 573,000 403,710 82,963 86,327 57,300 70,465 297,055 During the year ended August 31, 2023, the principal amount of $ 573,000 6,028 1,750 522,777 nil On September 18, 2023, Mast Hill fully exercised all warrants granted under the terms and conditions of the $ 573,000 53,567 Novo Integrated – FirstFire Global Opportunities Fund, LLC On March 21, 2023, the Company entered into a securities purchase agreement (the “SPA”) with FirstFire Global Opportunities Fund, LLC (“FirstFire”) pursuant to which the Company issued an 12 March 21, 2024 573,000 100,000 12 57,300 515,700 1.75 Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay accrued interest monthly as well as the Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the 2023 FirstFire Note at any time prior to the date that an event of default (as provided in the 2023 FirstFire Note) occurs at an amount equal to the Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any event of default, the 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the Principal Sum then outstanding plus accrued interest multiplied by 125 16 The 2023 FirstFire Warrant is exercisable for five years from March 21, 2023, at an exercise price of $ 2.50 93,811 ● Expected life of 5.0 ● Volatility of 251 ● Dividend yield of 0 ● Risk free interest rate of 3.73 As additional consideration for the purchase of the 2023 FirstFire Note and pursuant to the terms of the SPA, on March 22, 2023, the Company issued 95,500 1,000,000 The principal amount of the $ 573,000 389,057 90,132 93,811 57,300 35,628 The effective conversion price was determined to be $ 1.188 1.390 66,068 The combined total discount is $ 342,938 190,209 nil During the three months ended November 30, 2023, the principal amount of $ 573,000 4,521 519,845 nil On October 12, 2023, FirstFire fully exercised all warrants granted under the terms and conditions of the $ 573,000 53,532 Novo Integrated – Mast Hill Fund, L.P. $445,000 Note, SPA, and Warrant On June 20, 2023, the Company entered into a securities purchase agreement (the “MH $445,000 SPA”) with Mast Hill, pursuant to which the Company issued an 12 June 20, 2024 445,000 77,662 12 44,500 400,500 1.75 Pursuant to the terms of the MH $445,000 Note, the Company agreed to pay accrued interest monthly as well as the MH $ 445,000 44,500 44,500 44,500 77,661 77,661 77,661 85 The Company may prepay the MH $445,000 Note at any time prior to the date that an Event of Default (as defined in the Note) (each an “MH $445,000 Event of Default”) occurs at an amount equal to the MH $445,000 Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any MH $445,000 Event of Default, the MH $445,000 Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the MH $445,000 Principal Sum then outstanding plus accrued interest multiplied by 125 The MH $445,000 Warrant is exercisable for five years from June 20, 2023, at an exercise price of $ 2.50 445,000 77,856 ● Expected life of 5.0 ● Volatility of 251 ● Dividend yield of 0 ● Risk free interest rate of 3.96 As additional consideration for the purchase of the MH $445,000 Note and pursuant to the terms of the MH $445,000 SPA, the Company issued 74,167 1,772,045 The principal amount of the $ 445,000 292,351 74,793 77,856 44,500 39,904 The effective conversion price was determined to be $ 1.150 1.535 97,978 The combined total discount is $ 335,031 83,300 185,823 Specific to the MH $445,000 Note, on July 20, 2023, the Company made a monthly interest payment of $ 4,243 4,535 4,535 4,389 On October 23, 2023, Mast Hill fully exercised all warrants granted under the terms and conditions of the $ 445,000 138,703 September 2023 Mast Hill SPA On September 12, 2023, the Company entered into a securities purchase agreement (the “September 2023 Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12 September 12, 2024 3,500,000 12 350,000 3,150,000 4.50 91.5 Pursuant to the terms of the September 2023 Mast Hill Note, the Company agreed to pay the principal sum and accrued interest as follows: (i) all accrued interest on December 12, 2023, (ii) $ 350,000 350,000 350,000 595,000 595,000 595,000 85 The Company may prepay the September 2023 Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Note) occurs at an amount equal to the principal sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any Event of Default, the September 2023 Mast Hill Note shall become immediately due and payable and the Company will pay to Mast Hill an amount equal to the principal sum then outstanding plus accrued interest multiplied by 125 16 The September 2023 Mast Hill SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the common stock underlying the September 2023 Mast Hill Note. Further, pursuant to the September 2023 Mast Hill SPA, the Company agreed to transfer its rights to the charges/mortgages evidenced by Instrument Nos. CE925256 (in the amount of CDN$ 1,600,000 1,800,000 1,772,045 The Company’s subsidiary, Acenzia Inc. (“Acenzia”), entered into a guaranty with Mast Hill on September 12, 2023. Acenzia guaranteed the repayment of the September 2023 Mast Hill Note and granted Mast Hill a security interest in Acenzia’s assets, including but not limited to, the property located at 1580 Rossi Drive, Tecumseh, Ontario, Canada. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. On September 12, 2023, the Company recorded a derivative liability of $ 3,071,653 ● Expected life of 1 ● Volatility of 182.17 ● Dividend yield of 0 ● Risk free interest rate of 5.42 The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible note. As at November 30, 2023, the fair value of the derivative liability was $ 2,487,726 583,927 ● Expected life of 0.79 ● Volatility of 193.48 ● Dividend yield of 0 ● Risk free interest rate of 5.16 The September 2023 Mast Hill Note contained a discount on note of $ 3,500,000 During the three months ended November 30, 2023, the Company amortized $ 755,464 2,744,536 September 2023 FirstFire SPA & Note On September 18, 2023, the Company entered into a securities purchase agreement (the “September 2023 FirstFire SPA”) with FirstFire Global Opportunities Fund, L.P. (“FirstFire”), pursuant to which the Company issued an 12 September 18, 2024 277,778 12 27,778 250,000 4.50 91.5 Pursuant to the terms of the September 2023 FirstFire Note, the Company agreed to pay the principal sum and accrued interest as follows: (i) all accrued interest on December 18, 2023, (ii) $ 27,778 27,778 27,778 47,222 47,222 47,222 85 The Company may prepay the September 2023 FirstFire Note at any time prior to the date that an event of default occurs at an amount equal to the principal sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any event of default, the September 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the principal sum then outstanding plus accrued interest multiplied by 125 16 The September 2023 FirstFire SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the common stock underlying the September 2023 FirstFire Note. In addition to the beneficial ownership limitations provided in the September 2023 FirstFire Note, the sum of the number of shares of common stock that may be issued under the September 2023 FirstFire SPA and September 2023 FirstFire Note shall be limited to 480,156 Acenzia entered into a guaranty with FirstFire on September 18, 2023. Acenzia guaranteed the repayment of the September 2023 FirstFire Note and granted FirstFire a security interest in Acenzia’s assets, including but not limited to the property located at 1580 Rossi Drive, Tecumseh, Ontario, Canada, which is junior in priority to the security interest granted by Acenzia to FirstFire. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. On September 18, 2023, the Company recorded a derivative liability of $ 200,136 ● Expected life of 1 ● Volatility of 180.36 ● Dividend yield of 0 ● Risk free interest rate of 5.44 The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible note. As at November 30, 2023, the fair value of the derivative liability was $ 198,534 1,602 ● Expected life of 0.80 ● Volatility of 193.48 ● Dividend yield of 0 ● Risk free interest rate of 5.16 The September 2023 FirstFire Note contained a discount on note of $ 235,414 During the three months ended November 30, 2023, the Company amortized $ 46,954 188,460 |
Debentures, Related Parties
Debentures, Related Parties | 3 Months Ended |
Nov. 30, 2023 | |
Debt Disclosure [Abstract] | |
Debentures, Related Parties | Note 12 – Debentures, Related Parties On September 30, 2013, the Company issued five debentures totaling CAD$ 6,402,512 6,225,163 8 September 30, 2016 September 30, 2019 December 1, 2023 On January 31, 2018, the debenture holders converted 75 3,894,809 414,965 1,047,588 4.11 the average price of the five trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $ 267,768 At November 30, 2023 and August 31, 2023, the amount of debentures outstanding was $ 913,474 916,824 |
Leases
Leases | 3 Months Ended |
Nov. 30, 2023 | |
Leases | |
Leases | Note 13 – Leases Operating leases The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2031. The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of November 30, 2023 and August 31, 2023: Schedule of Lease Related Assets and Liabilities November 30, August 31, 2023 2023 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 1,870,204 $ 1,983,898 Total lease assets $ 1,870,204 $ 1,983,898 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 413,506 $ 415,392 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,585,667 1,693,577 Total lease liability $ 1,999,173 $ 2,108,969 Future minimum operating lease payments are as follows: Schedule of Operating Lease Payments Twelve Months Ending November 30, 2024 $ 568,536 2025 494,272 2026 512,495 2027 417,394 2028 223,188 Thereafter 254,641 Total payments 2,470,526 Amount representing interest (471,353 ) Lease obligation, net 1,999,173 Less lease obligation, current portion 413,506 Lease obligation, long-term portion $ 1,585,667 During the three months ended November 30, 2023, the Company did not enter into any new lease obligation. The lease expense for the three months ended November 30, 2023 and 2022 was $ 149,877 209,846 145,545 202,465 3.88 8 Finance Leases The Company leases certain equipment under lease contracts that are accounted for as finance leases. If the contracts meet the criteria for a finance lease, the related equipment underlying the lease contract is capitalized and amortized over its estimated useful life. If the cost of the equipment is not available, the Company calculates the cost by taking the present value of the lease payments using an implicit borrowing rate of 5 The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at November 30, 2023 and August 31, 2023 is as follows: Schedule of Finance Leases November 30, August 31, 2023 2023 Cost $ 209,457 $ 209,457 Accumulated amortization (209,457) (209,457) Net book value $ - $ - Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Twelve Months Ending November 30, 2024 $ 8,973 Total payments 8,973 Amount representing interest (66 ) Lease obligation, net 8,907 Less lease obligation, current portion (8,907 ) Lease obligation, long-term portion $ - |
Stockholders_ Equity
Stockholders’ Equity | 3 Months Ended |
Nov. 30, 2023 | |
Equity [Abstract] | |
Stockholders’ Equity | Note 14 – Stockholders’ Equity Reverse Stock Split On November 6, 2023, the Company effectuated a 1-for-10 reverse stock split Convertible Preferred Stock The Company has authorized 1,000,000 0.001 0 0 Common Stock The Company has authorized 499,000,000 0.001 17,291,192 15,759,325 During the three-month period ended November, 2023, the Company issued common stock as follows: ● 80,200 3 80,200 ● 160,200 5 160,200 ● 75,000 September 5, 2023 ● 53,567 573,000 September 18, 2023 ● 75,000 September 18, 2023 ● 519,845 573,000 4,521 577,521 September 21, 2023 ● 75,000 October 3, 2023 ● 73,767 October 9, 2023 ● 53,532 573,000 October 12, 2023 ● 75,000 October 18, 2023 ● 138,703 445,000 October 23, 2023 ● 75,000 November 8, 2023 ● 30,675 November 21, 2023 ● 18,405 November 21, 2023 ● 27,973 1-for-10 reverse stock split Common Stock to be Issued As of November 30, 2023, in connection with the acquisition of 1285 Canada and Poling Taddeo Hovius Physiotherapy Professional Corp, the Company has allotted and is obligated to issue 17,375 44,443 Stock Options On September 8, 2015, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 50,000 On January 16, 2018, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2018 Incentive Compensation Plan (the “2018 Plan”). Under the 2018 Plan, 100,000 86,490 On February 9, 2021, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Under the 2021 Plan, a total of 450,000 the maximum aggregate number of shares that may be issued under the 2021 Plan may be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2024, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan, effective January 1, 2022 and January 1, 2023. As of November 30, 2023, the 2021 Plan had 75,463 On July 26, 2023 and September 29, 2023, the Company’s Board of Directors and stockholders, respectively, approved the Novo Integrated Sciences, Inc. 2023 Equity Incentive Plan (the “2023 Plan”). Under the 2023 Plan, a total of 2,500,000 2,500,000 The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2023 371,423 11.44 3.98 $ 16,000 Granted - Forfeited - Exercised - Outstanding, November 30, 2023 371,423 11.44 3.73 $ - Exercisable, November 30, 2023 371,423 $ 11.44 3.73 $ - The exercise price for stock options outstanding at November 30, 2023: Schedule of Options Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 22,715 $ 13.30 22,715 $ 13.30 54,200 16.00 54,200 16.00 4,800 18.70 4,800 18.70 77,500 30.00 77,500 30.00 7,260 38.00 7,260 38.00 1,000 50.00 1,000 50.00 3,948 19.00 3,948 19.00 200,000 1.32 200,000 1.32 371,423 371,423 No options were granted during the three months ended November 30, 2023 and 2022. The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $ nil 60,887 nil Warrants The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2023 806,254 $ 12.05 3.71 $ 106,960 Granted - Forfeited - Exercised (518,061 ) Outstanding, November 30, 2023 288,193 $ 30.46 3.46 $ 5,400 Exercisable, November 30, 2023 288,193 $ 30.46 3.46 $ 5,400 The exercise price for warrants outstanding at November 30, 2023: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 261,193 $ 33.50 27,000 1.00 288,193 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Nov. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 15 – Commitments and Contingencies Litigation The Company is party to certain legal proceedings from time-to-time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our condensed consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s unaudited condensed consolidated financial position as of November 30, 2023, results of operations, cash flows or liquidity of the Company. During the period ended November 30, 2023, the Company incurred $ 652,174 |
Segment Reporting
Segment Reporting | 3 Months Ended |
Nov. 30, 2023 | |
Segment Reporting [Abstract] | |
Segment Reporting | Note 16 – Segment Reporting ASC Topic 280, Segment Reporting The following tables summarize the Company’s segment information for the three months ended November 30, 2023 and 2022: Schedule of Segment Reporting Information Three Months Ended November 30, 2023 2022 Sales Healthcare services $ 2,044,510 $ 2,021,213 Product manufacturing and development 1,768,458 790,478 Corporate 78,250 607,589 Sales $ 3,891,218 $ 3,419,280 Gross profit Healthcare services $ 676,416 $ 784,031 Product manufacturing and development 1,189,352 347,914 Corporate 78,250 607,588 Gross profit $ 1,944,018 $ 1,739,533 (Loss) income from operations Healthcare services $ (80,327 ) $ (151,691 ) Product manufacturing and development 108,702 (554,842 ) Corporate (3,346,012 ) (1,535,427 ) Income (loss) from operations $ (3,317,637 ) $ (2,241,960 ) Depreciation and amortization Healthcare services $ 30,035 $ 28,968 Product manufacturing and development 262,927 309,042 Corporate 279,442 248,156 Depreciation and amortization $ 572,404 $ 586,166 Capital expenditures Healthcare services $ - $ - Product manufacturing and development - - Corporate - - Capital expenditures $ - $ - Interest expenses Healthcare services $ 20,532 $ 36,303 Product manufacturing and development 462 2,464 Corporate 122,380 128,476 Interest expenses $ 143,374 $ 167,243 Net (loss) income Healthcare services $ (98,640 ) $ (185,713 ) Product manufacturing and development 48,883 (578,576 ) Corporate (4,610,966 ) (3,172,447 ) Net loss $ (4,660,723 ) $ (3,936,736 ) As of November 30, 2023 As of August 31, 2023 Total assets Healthcare services $ 5,002,855 $ 5,158,851 Product Sales 18,748,475 17,993,652 Corporate 13,493,054 12,410,544 $ 37,244,384 $ 35,563,047 Accounts receivable Healthcare services $ 672,841 $ 697,440 Product Sales 1,868,387 765,388 Corporate 94,946 4,200 $ 2,636,174 $ 1,467,028 Intangible assets Healthcare services $ 111,172 $ 120,163 Product Sales 3,592,425 3,818,313 Corporate 12,000,621 12,280,063 $ 15,704,218 $ 16,218,539 Goodwill Healthcare services $ 518,918 $ 520,821 Product Sales 7,035,861 7,061,662 Corporate - - $ 7,554,779 $ 7,582,483 |
Subsequent Events
Subsequent Events | 3 Months Ended |
Nov. 30, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 17 – Subsequent Events Purchase and Sale Agreement – Ophir Collection On November 21, 2023, the Company entered into a Purchase and Sale Agreement (“Ophir Agreement”) between the Company and Blake Alsbrook, solely in his capacity as Court-appointed successor receiver (the “Successor Receiver”) in Ocean Thermal Energy Corporation v. C. Robert Coe II, et al., United States District Court for the Central District of California (the “Court”) Case No. 2:19-cv-04299 VAP (JPRx) (the “Action”). Pursuant to the terms of the Ophir Agreement, the Company agreed to purchase, and the Successor Receiver agreed to sell to the Company, the Ophir Collection (as hereinafter defined), subject to the contingencies outlined in the Ophir Agreement, including Court approval, which approval was received on December 1, 2023. The Ophir Agreement was effective upon execution by both parties; however, the Ophir Agreement was subject to approval by the Court. Pursuant to the Court’s July 2, 2019 order in the Action, as modified by the Court’s February 25, 2022 order in the Action, the Successor Receiver has possession of and right to sell a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir Collection”. Together, the Court’s July 2, 2019 order appointing the original receiver, the Court’s December 3, 2019, order appointing the Successor Receiver, and the Court’s February 25, 2022, order are referred to collectively as the “Receivership Orders.” The Receivership Orders authorized the Successor Receiver to take sole custody, possession, and control of the Ophir Collection and to sell, assign, transfer, convey and deliver title and rights in and to the Ophir Collection subject to the approval of the Court to protect the interests of certain identified creditors. Within two business days following the Company’s execution of the Ophir Agreement, the Company was required to, and did, deposit $ 25,000 Pursuant to the terms of the Ophir Agreement, the Company agreed to pay $ 60,000,000 (i) The Company has the right, at all times after November 21, 2023, to conduct a full and unfettered inspection of the Ophir Collection. While the Company has the right to inspect the Ophir Collection prior to closing, the Company’s inspection will not be a contingency to closing and the inability of the Company to inspect (or the Company’s decision not to inspect) the Ophir Collection prior to closing will not delay or prevent closing. (ii) After the Successor Receiver obtains Court approval of the Ophir Agreement, the Company will cause $ 59,975,000 60,000,000 (iii) Within one business day thereafter, the Successor Receiver will assign, transfer, convey and deliver free and clear title and interest in and to, and possession of, the Ophir Collection to the Company. Mast Hill Conversion of Debt on $445,000 Promissory Note On December 21, 2023, the $ 454,071 445,000 457,128 0.99331 445,000 Interest Payment on September 2023 Mast Hill Note On December 12, 2023, the Company made an interest-only payment of $ 104,712 Interest Payment on September 2023 FirstFire Note On December 18, 2023, the Company made an interest-only payment of $ 8,333 Officer Option Grant On January 16, 2024, the Board of Directors granted to Christopher David, the Company’s President, Chief Operating Officer and member of the Board of Directors, an option to purchase 200,000 0.78 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Nov. 30, 2023 | |
Accounting Policies [Abstract] | |
Use of Estimates | Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, valuation of derivative liability, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. |
Principles of Consolidation | Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls, including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. |
Noncontrolling Interest | Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss. |
Cash Equivalents | Cash Equivalents For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. |
Accounts Receivable | Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of November 30, 2023 and August 31, 2023, the allowance for uncollectible accounts receivable was $ 855,116 864,215 |
Inventory | Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of November 30, 2023 and August 31, 2023, the Company’s allowance for slow moving or obsolete inventory was $ nil nil |
Other Receivables | Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the three months ended November 30, 2023 and year ended August 31, 2023, the Company wrote off $ nil nil |
Property and Equipment | Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5 |
Leases | Leases The Company applies the provisions of ASC Topic 842, Leases |
Long-Lived Assets | Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment no |
Intangible Assets | Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its review at November 30, 2023, the Company believes there was no |
Right-of-use Assets | Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months |
Goodwill | Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. Based on its review at November 30, 2023, the Company believes there was no Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Beginning balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Foreign currency translation adjustment (675 ) (443 ) (783 ) (25,801 ) (2 ) (27,704 ) Balance, November 30, 2023 $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 Ending balance $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 |
Fair Value of Financial Instruments | Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of November 30, 2023 and August 31, 2023, respectively, the Company did not identify any financial assets and liabilities required to be presented on the condensed consolidated balance sheet at fair value, except for contingent liability which is carried at fair value using Level 1 inputs and derivative liability which is carried at fair value using Level 3 inputs. |
Derivative Financial Instruments | Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives. |
Revenue Recognition | Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery. In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying condensed consolidated balance sheets. Sales returns and allowances were insignificant for the three months ended November 30, 2023 and 2022. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. |
Income Taxes | Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. |
Stock-Based Compensation | Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation |
Basic and Diluted Earnings Per Share | Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 659,616 1,860,950 3,786,454 17,375 Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented. |
Foreign Currency Transactions and Comprehensive Income | Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gain of $ 108,976 922,609 |
Condensed Consolidated Statements of Cash Flows | Condensed Consolidated Statements of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the condensed consolidated balance sheets. |
Segment Reporting | Segment Reporting ASC Topic 280, Segment Reporting two |
Reclassifications | Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying condensed consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances. |
Organization and Basis of Pre_2
Organization and Basis of Presentation (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Foreign Currency Translation, Exchange Rate Used | Schedule of Foreign Currency Translation, Exchange Rate Used November 30, 2023 November 30, 2022 August 31, 2023 Period end: CAD to USD exchange rate $ 0.7363 $ 0.7403 $ 0.7390 Average period: CAD to USD exchange rate $ 0.7324 $ 0.7414 $ 0.7426 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Estimated Useful lives of Assets | Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5 |
Schedule of Intangible Assets Amortized Estimated Useful Lives | The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 |
Schedule of Changes in Goodwill | Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Beginning balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Foreign currency translation adjustment (675 ) (443 ) (783 ) (25,801 ) (2 ) (27,704 ) Balance, November 30, 2023 $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 Ending balance $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 |
Accounts Receivables, Net (Tabl
Accounts Receivables, Net (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Receivables [Abstract] | |
Schedule of Accounts Receivable, Net | Accounts receivables, net at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Accounts Receivable, Net November 30, August 31, 2023 2023 Trade receivables $ 3,412,783 $ 2,223,243 Amounts earned but not billed 78,507 108,000 Accounts receivables gross 3,491,290 2,331,243 Allowance for doubtful accounts (855,116 ) (864,215 ) Accounts receivable, net $ 2,636,174 $ 1,467,028 |
Inventory (Tables)
Inventory (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | Inventory at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Inventory November 30, August 31, 2023 2023 Raw materials $ 516,811 $ 388,391 Work in process 108,244 81,696 Finished Goods 645,780 636,896 Inventory Gross 1,270,835 1,106,983 Allowance for slow moving and obsolete inventory - - Inventory, net $ 1,270,835 $ 1,106,983 |
Other Receivables (Tables)
Other Receivables (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Receivables [Abstract] | |
Schedule of Other Receivables | Other receivables at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Other Receivables November 30, August 31, Advance to corporation; accrues interest at 12 January 31, 2024 $ 73,630 $ 73,900 Advance to corporation; accrues interest at 12 February 1, 2024 532,433 534,386 Advance to corporation; accrues interest at 10 February 1, 2024 441,679 443,298 Total other receivables 1,047,742 1,051,584 Current portion (1,047,742 ) (1,051,584 ) Long-term portion $ - $ - |
Property and Equipment (Tables)
Property and Equipment (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | Property and equipment at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Property and Equipment November 30, August 31, 2023 2023 Land $ 441,780 $ 443,400 Building 3,313,350 3,325,500 Leasehold improvements 838,297 841,371 Clinical equipment 1,909,678 1,916,681 Computer equipment 33,381 33,504 Office equipment 44,400 44,502 Furniture and fixtures 38,149 38,289 Property and Equipment gross 6,619,035 6,643,247 Accumulated depreciation (1,312,422 ) (1,253,209 ) Total $ 5,306,613 $ 5,390,038 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | Intangible assets at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Intangible Assets November 30, August 31, 2023 2023 Land use rights $ 11,573,321 $ 11,573,321 Intellectual property 7,487,410 7,497,746 Customer relationships 2,287,746 2,291,058 Brand names 1,921,375 1,928,421 Finite lived intangible assets, gross 23,269,852 23,290,546 Accumulated amortization (7,565,634 ) (7,072,007 ) Total $ 15,704,218 $ 16,218,539 |
Schedule of Expected Amortization Expense of intangible Assets | Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of intangible Assets Twelve Months Ending November 30, 2024 $ 2,003,586 2025 1,820,324 2026 1,454,624 2027 1,208,004 2028 639,025 Thereafter 8,578,655 Total $ 15,704,218 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses | Accrued expenses at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Accrued Expenses November 30, August 31, 2023 2023 Accrued liabilities $ 1,049,543 $ 961,897 Accrued payroll 215,936 236,218 Unearned revenue 35,070 35,434 Accrued expense $ 1,300,549 $ 1,233,549 |
Government Loans and Notes Pa_2
Government Loans and Notes Payable (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Government Loans And Notes Payable | |
Schedule of Governmental Loans and Note Payable | Notes payable at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Governmental Loans and Note Payable November 30, August 31, 2023 2023 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program ( A 88,356 88,680 Note payable to the Small Business Administration. The note bears interest at 3.75 190 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 4,000 December 2, 2028 28,589 28,693 Note payable received May 25, 2023, accruing interest at 18 - 73,900 Note payable received May 10, 2023, accruing interest at 15 - 110,850 Total government loans and notes payable 157,265 342,443 Less current portion (93,488 ) (277,405 ) Long-term portion $ 63,777 $ 65,038 (A) The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 58,904 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,452 |
Schedule of Future Maturities Outstanding of government Loans and Notes Payable | Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of government Loans and Notes Payable Twelve Months Ending November 30, 2024 $ 93,488 2025 6,470 2026 6,469 2027 6,469 2028 6,469 Thereafter 37,900 Total $ 157,265 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Leases | |
Schedule of Lease Related Assets and Liabilities | The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of November 30, 2023 and August 31, 2023: Schedule of Lease Related Assets and Liabilities November 30, August 31, 2023 2023 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 1,870,204 $ 1,983,898 Total lease assets $ 1,870,204 $ 1,983,898 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 413,506 $ 415,392 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,585,667 1,693,577 Total lease liability $ 1,999,173 $ 2,108,969 |
Schedule of Operating Lease Payments | Future minimum operating lease payments are as follows: Schedule of Operating Lease Payments Twelve Months Ending November 30, 2024 $ 568,536 2025 494,272 2026 512,495 2027 417,394 2028 223,188 Thereafter 254,641 Total payments 2,470,526 Amount representing interest (471,353 ) Lease obligation, net 1,999,173 Less lease obligation, current portion 413,506 Lease obligation, long-term portion $ 1,585,667 |
Schedule of Finance Leases | The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at November 30, 2023 and August 31, 2023 is as follows: Schedule of Finance Leases November 30, August 31, 2023 2023 Cost $ 209,457 $ 209,457 Accumulated amortization (209,457) (209,457) Net book value $ - $ - |
Schedule of Future Minimum Lease Payments | Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Twelve Months Ending November 30, 2024 $ 8,973 Total payments 8,973 Amount representing interest (66 ) Lease obligation, net 8,907 Less lease obligation, current portion (8,907 ) Lease obligation, long-term portion $ - |
Stockholders_ Equity (Tables)
Stockholders’ Equity (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Equity [Abstract] | |
Schedule of Stock Option Activity | The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2023 371,423 11.44 3.98 $ 16,000 Granted - Forfeited - Exercised - Outstanding, November 30, 2023 371,423 11.44 3.73 $ - Exercisable, November 30, 2023 371,423 $ 11.44 3.73 $ - |
Schedule of Options Outstanding and Exercisable | The exercise price for stock options outstanding at November 30, 2023: Schedule of Options Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 22,715 $ 13.30 22,715 $ 13.30 54,200 16.00 54,200 16.00 4,800 18.70 4,800 18.70 77,500 30.00 77,500 30.00 7,260 38.00 7,260 38.00 1,000 50.00 1,000 50.00 3,948 19.00 3,948 19.00 200,000 1.32 200,000 1.32 371,423 371,423 |
Schedule of Warrant Activity | The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2023 806,254 $ 12.05 3.71 $ 106,960 Granted - Forfeited - Exercised (518,061 ) Outstanding, November 30, 2023 288,193 $ 30.46 3.46 $ 5,400 Exercisable, November 30, 2023 288,193 $ 30.46 3.46 $ 5,400 |
Schedule of Warrants Outstanding | The exercise price for warrants outstanding at November 30, 2023: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 261,193 $ 33.50 27,000 1.00 288,193 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 3 Months Ended |
Nov. 30, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Segment Reporting Information | The following tables summarize the Company’s segment information for the three months ended November 30, 2023 and 2022: Schedule of Segment Reporting Information Three Months Ended November 30, 2023 2022 Sales Healthcare services $ 2,044,510 $ 2,021,213 Product manufacturing and development 1,768,458 790,478 Corporate 78,250 607,589 Sales $ 3,891,218 $ 3,419,280 Gross profit Healthcare services $ 676,416 $ 784,031 Product manufacturing and development 1,189,352 347,914 Corporate 78,250 607,588 Gross profit $ 1,944,018 $ 1,739,533 (Loss) income from operations Healthcare services $ (80,327 ) $ (151,691 ) Product manufacturing and development 108,702 (554,842 ) Corporate (3,346,012 ) (1,535,427 ) Income (loss) from operations $ (3,317,637 ) $ (2,241,960 ) Depreciation and amortization Healthcare services $ 30,035 $ 28,968 Product manufacturing and development 262,927 309,042 Corporate 279,442 248,156 Depreciation and amortization $ 572,404 $ 586,166 Capital expenditures Healthcare services $ - $ - Product manufacturing and development - - Corporate - - Capital expenditures $ - $ - Interest expenses Healthcare services $ 20,532 $ 36,303 Product manufacturing and development 462 2,464 Corporate 122,380 128,476 Interest expenses $ 143,374 $ 167,243 Net (loss) income Healthcare services $ (98,640 ) $ (185,713 ) Product manufacturing and development 48,883 (578,576 ) Corporate (4,610,966 ) (3,172,447 ) Net loss $ (4,660,723 ) $ (3,936,736 ) As of November 30, 2023 As of August 31, 2023 Total assets Healthcare services $ 5,002,855 $ 5,158,851 Product Sales 18,748,475 17,993,652 Corporate 13,493,054 12,410,544 $ 37,244,384 $ 35,563,047 Accounts receivable Healthcare services $ 672,841 $ 697,440 Product Sales 1,868,387 765,388 Corporate 94,946 4,200 $ 2,636,174 $ 1,467,028 Intangible assets Healthcare services $ 111,172 $ 120,163 Product Sales 3,592,425 3,818,313 Corporate 12,000,621 12,280,063 $ 15,704,218 $ 16,218,539 Goodwill Healthcare services $ 518,918 $ 520,821 Product Sales 7,035,861 7,061,662 Corporate - - $ 7,554,779 $ 7,582,483 |
Schedule of Foreign Currency Tr
Schedule of Foreign Currency Translation, Exchange Rate Used (Details) | Nov. 30, 2023 | Aug. 31, 2023 | Nov. 30, 2022 |
Period End [Member] | |||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Foreign currency exchange rate | 0.7363 | 0.7390 | 0.7403 |
Average Period [Member] | |||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Foreign currency exchange rate | 0.7324 | 0.7426 | 0.7414 |
Organization and Basis of Pre_3
Organization and Basis of Presentation (Details Narrative) - USD ($) | 3 Months Ended | ||||
Nov. 07, 2023 | Nov. 06, 2023 | May 09, 2017 | Apr. 25, 2017 | Nov. 30, 2023 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Reverse stock split | 1-for-10 reverse stock split | 1-for-10 reverse stock split | 1-for-10 reverse stock split | ||
Parent Company [Member] | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Common stock issued in connection with reverse merger transaction | $ 6,904 | ||||
Share Exchange Agreement [Member] | NHL [Member] | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Number of restricted shares of common stock, shares | 1,677,974 | ||||
Percentage of common stock issued and outstanding | 85% |
Schedule of Estimated Useful li
Schedule of Estimated Useful lives of Assets (Details) | Nov. 30, 2023 |
Building [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, estimated lives | 30 years |
Leasehold Improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, estimated lives | 5 years |
Clinical Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, estimated lives | 5 years |
Computer Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, estimated lives | 3 years |
Office Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, estimated lives | 5 years |
Furniture and Fixtures [Member] | |
Property, Plant and Equipment [Line Items] | |
Property and equipment, estimated lives | 5 years |
Schedule of Intangible Assets A
Schedule of Intangible Assets Amortized Estimated Useful Lives (Details) | Nov. 30, 2023 |
Land Use Rights [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Intangible assets, estimated lives | 50 years |
Intellectual Property [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Intangible assets, estimated lives | 7 years |
Customer Relationships [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Intangible assets, estimated lives | 5 years |
Brand Names [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Intangible assets, estimated lives | 7 years |
Schedule of Changes in Goodwill
Schedule of Changes in Goodwill (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Nov. 30, 2023 | Aug. 31, 2023 | |
Beginning balance | $ 7,582,483 | $ 7,825,844 |
Foreign currency translation adjustment | (27,704) | (243,361) |
Ending balance | 7,554,779 | 7,582,483 |
APKA Health, Inc. [Member] | ||
Beginning balance | 184,750 | 190,678 |
Foreign currency translation adjustment | (675) | (5,928) |
Ending balance | 184,075 | 184,750 |
Executive Fitness Leaders [Member] | ||
Beginning balance | 121,196 | 125,088 |
Foreign currency translation adjustment | (443) | (3,892) |
Ending balance | 120,753 | 121,196 |
Rockland [Member] | ||
Beginning balance | 214,310 | 221,188 |
Foreign currency translation adjustment | (783) | (6,878) |
Ending balance | 213,527 | 214,310 |
Acenzia Inc [Member] | ||
Beginning balance | 7,061,662 | 7,288,307 |
Foreign currency translation adjustment | (25,801) | (226,645) |
Ending balance | 7,035,861 | 7,061,662 |
12858461 Canada Corp [Member] | ||
Beginning balance | 565 | 583 |
Foreign currency translation adjustment | (2) | (18) |
Ending balance | $ 563 | $ 565 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) | 3 Months Ended | 12 Months Ended | ||
Nov. 07, 2023 shares | Nov. 30, 2023 USD ($) Integer shares | Nov. 30, 2022 USD ($) shares | Aug. 31, 2023 USD ($) | |
Allowance for uncollectible accounts receivable | $ 855,116 | $ 864,215 | ||
Inventory | ||||
Other receivable written off | ||||
Impairment of long-lived assets | 0 | |||
Impairment of intangible assets | $ 0 | |||
Contract lease term | 12 months | |||
Goodwill impairment charge | ||||
Debt conversion, converted instrument, shares issued | shares | 27,973 | |||
Foreign currency translation gain (loss) | $ 108,976 | $ (420,982) | $ 922,609 | |
Number of reportable segments | Integer | 2 | |||
Common Stock [Member] | ||||
Debt conversion, converted instrument, shares issued | shares | 3,786,454 | |||
Common Stock To Be Issued [Member] | ||||
Debt conversion, converted instrument, shares issued | shares | 17,375 | |||
Options/Warrants Outstanding [Member] | ||||
Potentially dilutive common stock options and warrants outstanding, shares | shares | 659,616 | 1,860,950 | ||
Terragenx Inc [Member] | ||||
Equity method investment, ownership percentage | 91% | |||
12858461 Canada Corp [Member] | ||||
Equity method investment, ownership percentage | 50.10% | |||
Novo Healthnet Kemptville Centre Inc [Member] | ||||
Equity method investment, ownership percentage | 80% | |||
Novo Earth Therapeutics Inc [Member] | ||||
Equity method investment, ownership percentage | 70% |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended |
Nov. 30, 2023 | Aug. 31, 2023 | |
6% Interest Rate [Member] | ||
Related Party Transaction [Line Items] | ||
Bearing interest rate | 6% | 6% |
13.75% Interest Rate [Member] | ||
Related Party Transaction [Line Items] | ||
Bearing interest rate | 13.75% | 13.75% |
Related Party [Member] | ||
Related Party Transaction [Line Items] | ||
Due to related parties | $ 458,266 | $ 533,001 |
Related Party [Member] | Non-Interest Bearing [Member] | ||
Related Party Transaction [Line Items] | ||
Due to related parties | 376,701 | 451,137 |
Related Party [Member] | 6% Interest Rate [Member] | ||
Related Party Transaction [Line Items] | ||
Due to related parties | 21,267 | |
Related Party [Member] | 13.75% Interest Rate [Member] | ||
Related Party Transaction [Line Items] | ||
Due to related parties | $ 81,565 | $ 60,597 |
Schedule of Accounts Receivable
Schedule of Accounts Receivable, Net (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Receivables [Abstract] | ||
Trade receivables | $ 3,412,783 | $ 2,223,243 |
Amounts earned but not billed | 78,507 | 108,000 |
Accounts receivables gross | 3,491,290 | 2,331,243 |
Allowance for doubtful accounts | (855,116) | (864,215) |
Accounts receivable, net | $ 2,636,174 | $ 1,467,028 |
Schedule of Inventory (Details)
Schedule of Inventory (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 516,811 | $ 388,391 |
Work in process | 108,244 | 81,696 |
Finished Goods | 645,780 | 636,896 |
Inventory Gross | 1,270,835 | 1,106,983 |
Allowance for slow moving and obsolete inventory | ||
Inventory, net | $ 1,270,835 | $ 1,106,983 |
Schedule of Other Receivables (
Schedule of Other Receivables (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Total other receivables | $ 1,047,742 | $ 1,051,584 |
Current portion | (1,047,742) | (1,051,584) |
Long-term portion | ||
Advance to Corporation One [Member] | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Total other receivables | 73,630 | 73,900 |
Advance to Corporation Two [Member] | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Total other receivables | 532,433 | 534,386 |
Advance to Corporation Three [Member] | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Total other receivables | $ 441,679 | $ 443,298 |
Schedule of Other Receivables_2
Schedule of Other Receivables (Details) (Parenthetical) | 3 Months Ended | 12 Months Ended |
Nov. 30, 2023 | Aug. 31, 2023 | |
Advance to Corporation One [Member] | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Percentage of interest accrued per annum | 12% | 12% |
Notes receivable due date | Jan. 31, 2024 | Jan. 31, 2024 |
Advance to Corporation Two [Member] | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Percentage of interest accrued per annum | 12% | 12% |
Notes receivable due date | Feb. 01, 2024 | Feb. 01, 2024 |
Advance to Corporation Three [Member] | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Percentage of interest accrued per annum | 10% | 10% |
Notes receivable due date | Feb. 01, 2024 | Feb. 01, 2024 |
Schedule of Property and Equipm
Schedule of Property and Equipment (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Property, Plant and Equipment [Line Items] | ||
Property and Equipment gross | $ 6,619,035 | $ 6,643,247 |
Accumulated depreciation | (1,312,422) | (1,253,209) |
Total | 5,306,613 | 5,390,038 |
Land [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment gross | 441,780 | 443,400 |
Building [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment gross | 3,313,350 | 3,325,500 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment gross | 838,297 | 841,371 |
Clinical Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment gross | 1,909,678 | 1,916,681 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment gross | 33,381 | 33,504 |
Office Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment gross | 44,400 | 44,502 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment gross | $ 38,149 | $ 38,289 |
Property and Equipment (Details
Property and Equipment (Details Narrative) - USD ($) | 3 Months Ended | |
Nov. 30, 2023 | Nov. 30, 2022 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 72,604 | $ 60,043 |
Schedule of Intangible Assets (
Schedule of Intangible Assets (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Finite-Lived Intangible Assets [Line Items] | ||
Finite lived intangible assets, gross | $ 23,269,852 | $ 23,290,546 |
Accumulated amortization | (7,565,634) | (7,072,007) |
Total | 15,704,218 | 16,218,539 |
Land Use Rights [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite lived intangible assets, gross | 11,573,321 | 11,573,321 |
Intellectual Property [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite lived intangible assets, gross | 7,487,410 | 7,497,746 |
Customer Relationships [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite lived intangible assets, gross | 2,287,746 | 2,291,058 |
Brand Names [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite lived intangible assets, gross | $ 1,921,375 | $ 1,928,421 |
Schedule of Expected Amortizati
Schedule of Expected Amortization Expense of intangible Assets (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2024 | $ 2,003,586 | |
2025 | 1,820,324 | |
2026 | 1,454,624 | |
2027 | 1,208,004 | |
2028 | 639,025 | |
Thereafter | 8,578,655 | |
Total | $ 15,704,218 | $ 16,218,539 |
Intangible Assets (Details Narr
Intangible Assets (Details Narrative) - USD ($) | 3 Months Ended | |
Nov. 30, 2023 | Nov. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Amortization of intangible assets | $ 499,800 | $ 526,123 |
Schedule of Accrued Expenses (D
Schedule of Accrued Expenses (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Payables and Accruals [Abstract] | ||
Accrued liabilities | $ 1,049,543 | $ 961,897 |
Accrued payroll | 215,936 | 236,218 |
Unearned revenue | 35,070 | 35,434 |
Accrued expense | $ 1,300,549 | $ 1,233,549 |
Schedule of Governmental Loans
Schedule of Governmental Loans and Note Payable (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Nov. 30, 2023 | Aug. 31, 2023 | ||
Short-Term Debt [Line Items] | |||
Total government loans and notes payable | $ 157,265 | $ 342,443 | |
Less current portion | (93,488) | (277,405) | |
Long-term portion | 63,777 | 65,038 | |
Notes Payable One [Member] | |||
Short-Term Debt [Line Items] | |||
Total government loans and notes payable | [1] | 88,356 | 88,680 |
Notes Payable Two [Member] | |||
Short-Term Debt [Line Items] | |||
Total government loans and notes payable | 40,320 | 40,320 | |
Notes Payable Three [Member] | |||
Short-Term Debt [Line Items] | |||
Total government loans and notes payable | $ 28,589 | $ 28,693 | |
Debt instrument, maturity date | Dec. 02, 2028 | Dec. 02, 2028 | |
Notes Payable Four [Member] | |||
Short-Term Debt [Line Items] | |||
Total government loans and notes payable | $ 73,900 | ||
Notes Payable Five [Member] | |||
Short-Term Debt [Line Items] | |||
Total government loans and notes payable | $ 110,850 | ||
[1]The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 58,904 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,452 |
Schedule of Governmental Loan_2
Schedule of Governmental Loans and Note Payable (Details) (Parenthetical) | 3 Months Ended | 12 Months Ended | ||
Nov. 30, 2023 USD ($) | Nov. 30, 2023 CAD ($) | Aug. 31, 2023 USD ($) | Nov. 30, 2023 CAD ($) | |
Short-Term Debt [Line Items] | ||||
Default in repayment rate | 75% | 75% | ||
Interest rate during fixed rate | 5% | 5% | ||
Canada Emergency Business Account Loan [Member] | ||||
Short-Term Debt [Line Items] | ||||
Debt instrument, maturity date | Jan. 18, 2024 | Jan. 18, 2024 | ||
Debt description | If the loan amount is paid on or before January 18, 2024, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before January 18, 2024, the Early Payment Credit will not apply | If the loan amount is paid on or before January 18, 2024, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before January 18, 2024, the Early Payment Credit will not apply | ||
Forgiveness percentage | 25% | 25% | ||
Canada Emergency Business Account Loan [Member] | Terragenx [Member] | ||||
Short-Term Debt [Line Items] | ||||
Notes Payable | $ 29,452 | $ 60,000 | ||
Repayment of debt | $ 20,000 | |||
Notes Payable Two [Member] | ||||
Short-Term Debt [Line Items] | ||||
Debt instrument, interest rate during period | 3.75% | 3.75% | 3.75% | |
Periodic payment | $ 190 | $ 190 | ||
Notes Payable Three [Member] | ||||
Short-Term Debt [Line Items] | ||||
Debt instrument, interest rate during period | 4.53% | 4.53% | 4.53% | |
Periodic payment | $ 4,000 | $ 4,000 | ||
Debt instrument, maturity date | Dec. 02, 2028 | Dec. 02, 2028 | Dec. 02, 2028 | |
Notes Payable Four [Member] | ||||
Short-Term Debt [Line Items] | ||||
Debt instrument, interest rate during period | 18% | 18% | 18% | |
Notes Payable Five [Member] | ||||
Short-Term Debt [Line Items] | ||||
Debt instrument, interest rate during period | 15% | 15% | 15% | |
Canada Emergency Business Account Loan [Member] | ||||
Short-Term Debt [Line Items] | ||||
Notes Payable | $ 58,904 | $ 80,000 |
Schedule of Future Maturities O
Schedule of Future Maturities Outstanding of government Loans and Notes Payable (Details) | Nov. 30, 2023 USD ($) |
Government Loans And Notes Payable | |
2024 | $ 93,488 |
2025 | 6,470 |
2026 | 6,469 |
2027 | 6,469 |
2028 | 6,469 |
Thereafter | 37,900 |
Total | $ 157,265 |
Convertible Notes Payable (Deta
Convertible Notes Payable (Details Narrative) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Aug. 18, 2024 USD ($) | Aug. 12, 2024 USD ($) | Jul. 18, 2024 USD ($) | Jul. 12, 2024 USD ($) | Jun. 18, 2024 USD ($) | Jun. 12, 2024 USD ($) | May 18, 2024 USD ($) | May 12, 2024 USD ($) | Apr. 20, 2024 USD ($) | Apr. 18, 2024 USD ($) | Apr. 12, 2024 USD ($) | Mar. 20, 2024 USD ($) | Mar. 18, 2024 USD ($) | Mar. 12, 2024 USD ($) | Feb. 21, 2024 USD ($) | Feb. 20, 2024 USD ($) | Jan. 23, 2024 USD ($) | Jan. 21, 2024 USD ($) | Jan. 20, 2024 USD ($) | Jan. 16, 2024 shares | Dec. 23, 2023 USD ($) | Dec. 21, 2023 USD ($) | Dec. 21, 2023 USD ($) shares | Dec. 20, 2023 USD ($) | Dec. 18, 2023 USD ($) | Dec. 12, 2023 USD ($) | Nov. 23, 2023 USD ($) | Nov. 21, 2023 USD ($) | Nov. 07, 2023 shares | Oct. 23, 2023 USD ($) shares | Oct. 21, 2023 USD ($) | Oct. 12, 2023 USD ($) shares | Sep. 23, 2023 USD ($) | Sep. 21, 2023 USD ($) | Sep. 18, 2023 USD ($) $ / shares shares | Sep. 12, 2023 USD ($) $ / shares shares | Sep. 12, 2023 CAD ($) shares | Aug. 23, 2023 USD ($) | Aug. 21, 2023 USD ($) shares | Jun. 20, 2023 USD ($) $ / shares shares | Jun. 20, 2023 USD ($) $ / shares shares | May 20, 2023 USD ($) | Mar. 21, 2023 USD ($) $ / shares shares | Feb. 24, 2023 shares | Feb. 23, 2023 USD ($) $ / shares shares | Nov. 14, 2022 USD ($) | Jun. 01, 2022 USD ($) | Dec. 14, 2021 USD ($) $ / shares shares | Nov. 17, 2021 USD ($) $ / shares shares | Sep. 30, 2023 USD ($) | Nov. 30, 2023 USD ($) shares | Nov. 30, 2022 USD ($) shares | Aug. 31, 2023 USD ($) shares | Oct. 20, 2023 USD ($) | Sep. 12, 2023 CAD ($) | Jul. 20, 2023 USD ($) | |
Debt face amount | $ 1,875,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, note holders issued warrants to purchase total, shares | shares | 22,388 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated value warrants | $ 351,240 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount on convertable note and additional paid in capital | 295,824 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan fees | $ 90,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt amortized discount | $ 1,075,928 | $ 1,490,513 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt converted into common stock | shares | 27,973 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share price | $ / shares | $ 33.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Redemption of warrants description | The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 1,579,176 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 375,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 1,103,959 | $ 558,668 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issuable upon exercise | 577,522 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change in fair value of derivative liability | (585,529) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt converted into common stock | shares | 457,128 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 445,000 | $ 445,000 | $ 3,500,000 | $ 445,000 | $ 445,000 | $ 573,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Sep. 12, 2024 | Sep. 12, 2024 | Jun. 20, 2024 | Feb. 23, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ / shares | $ 4.50 | $ 1.75 | $ 1.75 | $ 1.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price of warrants or rights | $ / shares | $ 2.50 | $ 2.50 | $ 2.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated value warrants | $ 86,327 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount | 57,300 | 2,744,536 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan fees | $ 39,904 | $ 39,904 | 70,465 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt amortized discount | $ 297,055 | $ 3,500,000 | 755,464 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value of the derivative liability | $ 3,071,653 | $ 2,487,726 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 6,028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt converted into common stock | shares | 522,777 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument aggregate principal amount | $ 573,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share price | $ / shares | $ 1.535 | $ 1.535 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 350,000 | $ 44,500 | $ 44,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 4,535 | $ 4,535 | $ 4,389 | $ 4,243 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, effective percentage | 12% | 12% | 12% | 12% | 12% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrant or right, number of shares | shares | 1,772,045 | 1,772,045 | 2,772,045 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued liabilities | $ 100,000 | $ 57,300 | $ 57,300 | $ 57,300 | $ 77,661 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of stock price trigger | 85% | 85% | 85% | 85% | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Administrative fees expense | $ 750 | $ 750 | $ 750 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Variable interest, percentage rate | 125% | 125% | 125% | 125% | 125% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of restricted shares | shares | 95,500 | 53,567 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of issued and outstanding common stock | 19.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other fees | 1,750 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, effective conversion price | $ / shares | $ 1.150 | $ 1.150 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | $ 97,978 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments for repurchase of warrants | $ 400,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issuable upon exercise | 445,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated value of the warrants | $ 77,856 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares new issues | shares | 1,772,045 | 1,772,045 | 74,167 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | $ 3,150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of stock price trigger | 0.915 | 0.915 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring charges | $ 1,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial instruments owned, mortgages | $ 1,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change in fair value of derivative liability | $ 583,927 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mast Hill Securities Purchase Agreement [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount | $ 104,712 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued liabilities | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mast Hill Securities Purchase Agreement [Member] | Forecast [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued liabilities | $ 595,000 | $ 595,000 | $ 595,000 | $ 350,000 | $ 77,661 | $ 350,000 | $ 77,661 | $ 350,000 | $ 44,500 | $ 44,500 | $ 100,000 | $ 445,000 | ||||||||||||||||||||||||||||||||||||||||||||
Mast Hill Securities Purchase Agreement [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrant or right, number of shares | shares | 77,662 | 77,662 | 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Variable interest, percentage rate | 16% | 16% | 16% | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Mast Hill Note and Mast Hill Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrumment converted amount | $ 515,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
MastHill Warrant Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of restricted shares | shares | 138,703 | 53,567 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from warrant exercises | $ 445,000 | $ 573,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 573,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Mar. 21, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ / shares | $ 1.75 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price of warrants or rights | $ / shares | $ 2.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated value warrants | $ 93,811 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount | 57,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan fees | 35,628 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt amortized discount | $ 342,938 | 190,209 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 4,521 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt converted into common stock | shares | 519,845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument aggregate principal amount | $ 573,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share price | $ / shares | $ 1.390 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, effective percentage | 12% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrant or right, number of shares | shares | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued liabilities | $ 57,300 | $ 57,300 | $ 57,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of stock price trigger | 85% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Administrative fees expense | $ 750 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variable interest, percentage rate | 125% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of restricted shares | shares | 95,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, effective conversion price | $ / shares | $ 1.188 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | $ 66,068 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] | Forecast [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued liabilities | $ 100,000 | $ 100,000 | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrant or right, number of shares | shares | 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variable interest, percentage rate | 16% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Fire Note and First Fire Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrumment converted amount | $ 515,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Fire Warrant Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 573,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of restricted shares | shares | 53,532 | 53,532 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from warrant exercises | $ 573,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
FirstFire Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 277,778 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Sep. 18, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ / shares | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount | $ 188,460 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt amortized discount | $ 235,414 | 46,954 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value of the derivative liability | $ 200,136 | 198,534 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 27,778 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, effective percentage | 12% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of stock price trigger | 85% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Administrative fees expense | $ 750 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variable interest, percentage rate | 125% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares new issues | shares | 480,156 | 480,156 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | $ 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of stock price trigger | 0.915 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change in fair value of derivative liability | $ 1,602 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
FirstFire Securities Purchase Agreement [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount | $ 8,333 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
FirstFire Securities Purchase Agreement [Member] | Forecast [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued liabilities | $ 47,222 | $ 47,222 | $ 47,222 | $ 27,778 | $ 27,778 | $ 27,778 | ||||||||||||||||||||||||||||||||||||||||||||||||||
FirstFire Securities Purchase Agreement [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variable interest, percentage rate | 16% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Terragenx Inc [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ownership percentage | 91% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Terragenx Inc [Member] | Promissory Notes Payment [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 1,875,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 948,874 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Terragenx Inc [Member] | Promissory Notes Payment and Extension [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 1,875,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 937,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 192,188 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Nov. 29, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jefferson Street Capital [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt converted into common stock | shares | 236,511 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 1,875,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 186,719 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Nov. 29, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 5,257,466 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding, term | 3 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares new issues | shares | 80,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 77,856 | $ 77,856 | 86,327 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | 93,811 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt converted into common stock | shares | 3,786,454 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issuable upon exercise | $ 520 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares new issues | shares | 400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares new issues | shares | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | 74,793 | 74,793 | 82,963 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | 90,132 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 11,409,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 292,351 | $ 292,351 | $ 403,710 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 389,057 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt amortized discount | $ 760,824 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt description | (i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Expected Term [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding, term | 5 years | 5 years | 5 years | 5 years | 4 years | 3 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability, measurement input, term | 1 year | 1 year | 1 year | 6 months 29 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Expected Term [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability, measurement input, term | 9 months 14 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Expected Term [Member] | FirstFire Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability, measurement input, term | 9 months 18 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants measurement input percentage | 251 | 251 | 251 | 252 | 275 | 300 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 180.36 | 182.17 | 148.20 | 182.17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Price Volatility [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 193.48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Price Volatility [Member] | FirstFire Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 193.48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants measurement input percentage | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Expected Dividend Rate [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Expected Dividend Rate [Member] | FirstFire Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants measurement input percentage | 3.96 | 3.96 | 3.73 | 4.09 | 1.23 | 0.85 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 5.44 | 5.42 | 4.55 | 5.42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Risk Free Interest Rate [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 5.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measurement Input, Risk Free Interest Rate [Member] | FirstFire Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liability measurement input percentage | 5.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 16,666,666 | 8,396,666 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate, Stated Percentage | 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Jun. 14, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ / shares | $ 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, note holders issued warrants to purchase total, shares | shares | 583,334 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price of warrants or rights | $ / shares | $ 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant maturity date | Dec. 14, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated value warrants | $ 7,680,156 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount on convertable note and additional paid in capital | 5,257,466 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount | 1,666,666 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan fees | 1,140,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt amortized discount | 8,064,132 | 4,241,429 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | 2,833,888 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration] | Convertible notes payable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value of the derivative liability | $ 1,390,380 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 32,559 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt converted into common stock | shares | 8,527,835 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrumment converted amount | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of derivative liability due to conversion | 1,390,380 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization payment | 3,001,442 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount | 167,554 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument aggregate principal amount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two Convertible Notes [Member] | Terragenx Inc [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 1,875,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate, Stated Percentage | 1% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | May 17, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 8,333,333 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt Two [Member] | Terragenx Inc [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 937,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt face amount | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount | 185,823 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt amortized discount | $ 335,031 | $ 83,300 |
Debentures, Related Parties (De
Debentures, Related Parties (Details Narrative) | 3 Months Ended | ||||||||
Nov. 07, 2023 shares | Nov. 02, 2021 | Jul. 21, 2020 USD ($) | Jan. 31, 2018 USD ($) $ / shares shares | Dec. 02, 2017 | Sep. 30, 2013 USD ($) | Nov. 30, 2023 USD ($) | Nov. 30, 2022 USD ($) | Sep. 30, 2013 CAD ($) | |
Short-Term Debt [Line Items] | |||||||||
Debentures, outstanding | $ 913,474 | $ 916,824 | |||||||
Debt converted, shares issued | shares | 27,973 | ||||||||
Repayment of related party debt | $ 267,768 | $ (72,402) | $ (48,480) | ||||||
Five Debentures [Member] | |||||||||
Short-Term Debt [Line Items] | |||||||||
Debentures, outstanding | $ 6,225,163 | $ 6,402,512 | |||||||
Debt interest rate | 8% | 8% | |||||||
Debt due date | Dec. 01, 2023 | Sep. 30, 2019 | Sep. 30, 2016 | ||||||
Debentures [Member] | |||||||||
Short-Term Debt [Line Items] | |||||||||
Debentures, outstanding | $ 3,894,809 | ||||||||
Percentage of debt converted | 75% | ||||||||
Accrued interest | $ 414,965 | ||||||||
Debt converted, shares issued | shares | 1,047,588 | ||||||||
Debt conversion price | $ / shares | $ 4.11 | ||||||||
Debt conversion description | the average price of the five trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. |
Schedule of Lease Related Asset
Schedule of Lease Related Assets and Liabilities (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Leases | ||
Operating lease assets | $ 1,870,204 | $ 1,983,898 |
Total lease assets | 1,870,204 | 1,983,898 |
Current liabilities- Operating lease liability | 413,506 | 415,392 |
Noncurrent liabilities - Operating lease liability | 1,585,667 | 1,693,577 |
Total lease liability | $ 1,999,173 | $ 2,108,969 |
Schedule of Operating Lease Pay
Schedule of Operating Lease Payments (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Leases | ||
2024 | $ 568,536 | |
2025 | 494,272 | |
2026 | 512,495 | |
2027 | 417,394 | |
2028 | 223,188 | |
Thereafter | 254,641 | |
Total payments | 2,470,526 | |
Amount representing interest | (471,353) | |
Total lease liability | 1,999,173 | $ 2,108,969 |
Less lease obligation, current portion | 413,506 | 415,392 |
Lease obligation, long-term portion | $ 1,585,667 | $ 1,693,577 |
Schedule of Finance Leases (Det
Schedule of Finance Leases (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Leases | ||
Cost | $ 209,457 | $ 209,457 |
Accumulated amortization | (209,457) | (209,457) |
Net book value | ||
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] | Property and equipment, net | Property and equipment, net |
Schedule of Future Minimum Leas
Schedule of Future Minimum Lease Payments (Details) - USD ($) | Nov. 30, 2023 | Aug. 31, 2023 |
Leases | ||
2024 | $ 8,973 | |
Total payments | 8,973 | |
Amount representing interest | (66) | |
Lease obligation, net | 8,907 | |
Less lease obligation, current portion | (8,907) | $ (11,744) |
Lease obligation, long-term portion |
Leases (Details Narrative)
Leases (Details Narrative) - USD ($) | 3 Months Ended | |
Nov. 30, 2023 | Nov. 30, 2022 | |
Leases | ||
Lease expense | $ 149,877 | $ 209,846 |
Cash paid under operating leases | $ 145,545 | $ 202,465 |
Weighted average remaning lease term | 3 years 10 months 17 days | |
Weighted average discount rate | 8% | |
Lease payments implicit borrowing rate | 5% |
Schedule of Stock Option Activi
Schedule of Stock Option Activity (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Nov. 30, 2023 | Aug. 31, 2023 | |
Equity [Abstract] | ||
Options outstanding, balance | 371,423 | |
Weighted average exercise price, outstanding, balance | $ 11.44 | |
Weighted average remaining contractual life, outstanding | 3 years 8 months 23 days | 3 years 11 months 23 days |
Aggregate intrinsic value, outstanding, balance | $ 16,000 | |
Options outstanding, granted | ||
Options outstanding, forfeited | ||
Options outstanding, exercised | ||
Options outstanding, balance | 371,423 | 371,423 |
Weighted average exercise price, outstanding, balance | $ 11.44 | $ 11.44 |
Aggregate intrinsic value, outstanding, balance | $ 16,000 | |
Options outstanding, exercisable | 371,423 | |
Weighted average exercise price, exercisable | $ 11.44 | |
Weighted average remaining contractual life, Exercisable | 3 years 8 months 23 days | |
Aggregate intrinsic value, Exercisable |
Schedule of Options Outstanding
Schedule of Options Outstanding and Exercisable (Details) - $ / shares | Nov. 30, 2023 | Aug. 31, 2023 |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 371,423 | 371,423 |
Number of options, exercisable | 371,423 | |
Exercise Price Range One [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 22,715 | |
Exercise price, outstanding | $ 13.30 | |
Number of options, exercisable | 22,715 | |
Exercise price, exercisable | $ 13.30 | |
Exercise Price Range Two [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 54,200 | |
Exercise price, outstanding | $ 16 | |
Number of options, exercisable | 54,200 | |
Exercise price, exercisable | $ 16 | |
Exercise Price Range Three [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 4,800 | |
Exercise price, outstanding | $ 18.70 | |
Number of options, exercisable | 4,800 | |
Exercise price, exercisable | $ 18.70 | |
Exercise Price Range Four [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 77,500 | |
Exercise price, outstanding | $ 30 | |
Number of options, exercisable | 77,500 | |
Exercise price, exercisable | $ 30 | |
Exercise Price Range Five [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 7,260 | |
Exercise price, outstanding | $ 38 | |
Number of options, exercisable | 7,260 | |
Exercise price, exercisable | $ 38 | |
Exercise Price Range Six [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 1,000 | |
Exercise price, outstanding | $ 50 | |
Number of options, exercisable | 1,000 | |
Exercise price, exercisable | $ 50 | |
Exercise Price Range Seven [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 3,948 | |
Exercise price, outstanding | $ 19 | |
Number of options, exercisable | 3,948 | |
Exercise price, exercisable | $ 19 | |
Exercise Price Range Eight [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of options, outstanding | 200,000 | |
Exercise price, outstanding | $ 1.32 | |
Number of options, exercisable | 200,000 | |
Exercise price, exercisable | $ 1.32 |
Schedule of Warrant Activity (D
Schedule of Warrant Activity (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Nov. 30, 2023 | Aug. 31, 2023 | |
Equity [Abstract] | ||
Warrants outstanding, beginning balance | 806,254 | |
Weighted average exercise price, outstanding, beginning balance | $ 12.05 | |
Weighted average remaining contractual life, outstanding, beginning balance | 3 years 5 months 15 days | 3 years 8 months 15 days |
Aggregate intrinsic value, outstanding, beginning balance | $ 106,960 | |
Warrants outstanding, granted | ||
Warrants outstanding, forfeited | ||
Warrants outstanding, exercised | (518,061) | |
Warrants outstanding, beginning balance | 288,193 | 806,254 |
Weighted average exercise price, outstanding, beginning balance | $ 30.46 | $ 12.05 |
Aggregate intrinsic value, outstanding, beginning balance | $ 5,400 | $ 106,960 |
Warrants outstanding, exercisable | 288,193 | |
Weighted average exercise price, exercisable | $ 30.46 | |
Weighted average remaining contractual life, exercisable | 3 years 5 months 15 days | |
Aggregate intrinsic value, exercisable | $ 5,400 |
Schedule of Warrants Outstandin
Schedule of Warrants Outstanding (Details) - $ / shares | Nov. 30, 2023 | Aug. 31, 2023 |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of Warrants, Outstanding and Exercisable | 288,193 | 806,254 |
Exercise Price Range One [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of Warrants, Outstanding and Exercisable | 261,193 | |
Exercise Price, Outstanding and Exercisable | $ 33.50 | |
Exercise Price Range Two [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of Warrants, Outstanding and Exercisable | 27,000 | |
Exercise Price, Outstanding and Exercisable | $ 1 | |
Exercise Price Range [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number of Warrants, Outstanding and Exercisable | 288,193 |
Stockholders_ Equity (Details N
Stockholders’ Equity (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | 15 Months Ended | |||||||||||||||||
Nov. 07, 2023 | Nov. 06, 2023 | Oct. 12, 2023 | Sep. 12, 2023 | Jun. 20, 2023 | Mar. 21, 2023 | Feb. 24, 2023 | Feb. 09, 2021 | Nov. 30, 2023 | Nov. 30, 2022 | Aug. 31, 2023 | Nov. 30, 2023 | Dec. 21, 2023 | Sep. 29, 2023 | Jul. 26, 2023 | Feb. 23, 2023 | Dec. 14, 2021 | Nov. 17, 2021 | Jan. 16, 2018 | Sep. 08, 2015 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Reverse stock split | 1-for-10 reverse stock split | 1-for-10 reverse stock split | 1-for-10 reverse stock split | |||||||||||||||||
Convertible preferred stock, shares authorized | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||
Convertible preferred stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||||
Convertible preferred stock, shares issued | 0 | 0 | 0 | |||||||||||||||||
Convertible preferred stock, shares outstanding | 0 | 0 | 0 | |||||||||||||||||
Common stock, shares authorized | 499,000,000 | 499,000,000 | 499,000,000 | |||||||||||||||||
Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||||
Common stock, shares issued | 17,291,192 | 15,759,325 | 17,291,192 | |||||||||||||||||
Common stock, shares outstanding | 17,291,192 | 15,759,325 | 17,291,192 | |||||||||||||||||
Proceeds of warrants | $ 240,400 | |||||||||||||||||||
Promissory note issued | $ 1,875,000 | |||||||||||||||||||
Debt conversion, converted instrument, shares issued | 27,973 | |||||||||||||||||||
Common stock to be issued | 44,443 | $ 1,217,293 | $ 44,443 | |||||||||||||||||
Stock option expense | $ 60,887 | |||||||||||||||||||
Unamortized stock option expense | ||||||||||||||||||||
2015 Incentive Compensation Plan [Member] | Maximum [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of common stock shares authorized | 50,000 | |||||||||||||||||||
2018 Incentiven Plan [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of common stock shares authorized | 100,000 | |||||||||||||||||||
Number of shares available for future grant | 86,490 | 86,490 | ||||||||||||||||||
2021 Equity Incentive Plan [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of common stock shares authorized | 450,000 | |||||||||||||||||||
Number of shares available for future grant | 75,463 | 75,463 | ||||||||||||||||||
Term of award description | the maximum aggregate number of shares that may be issued under the 2021 Plan may be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2024, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan, effective January 1, 2022 and January 1, 2023. As of November 30, 2023, the 2021 Plan had 75,463 shares available for award; however, the Company does not intend to issue any additional grants under the 2021 Plan | |||||||||||||||||||
Two Thousand And Twenty Three Equity Incentive Plan [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of common stock shares authorized | 2,500,000 | 2,500,000 | ||||||||||||||||||
Taddeo Hovius Physiotherapy Professional Corp [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Shares issued for acquisition, shares | 17,375 | |||||||||||||||||||
Common stock to be issued | $ 44,443 | $ 44,443 | ||||||||||||||||||
Board of Directors Chairman [Member] | Two Thousand And Twenty Three Equity Incentive Plan [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of common stock shares authorized | 2,500,000 | 2,500,000 | ||||||||||||||||||
Share Exchange Agreement One [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 75,000 | |||||||||||||||||||
Shares issuance date | Sep. 05, 2023 | |||||||||||||||||||
Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Units issued for cash, net of offering costs | 1,772,045 | 74,167 | ||||||||||||||||||
Number of restricted shares | 95,500 | 53,567 | ||||||||||||||||||
Shares issuance date | Sep. 18, 2023 | |||||||||||||||||||
Promissory note issued | $ 3,500,000 | $ 445,000 | $ 445,000 | $ 573,000 | ||||||||||||||||
Interest | $ 6,028 | |||||||||||||||||||
Debt conversion, converted instrument, shares issued | 522,777 | |||||||||||||||||||
Consulting Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 75,000 | |||||||||||||||||||
Shares issuance date | Oct. 12, 2023 | Sep. 18, 2023 | ||||||||||||||||||
Securities Purchase Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 519,845 | |||||||||||||||||||
Shares issuance date | Sep. 21, 2023 | |||||||||||||||||||
Promissory note issued | $ 573,000 | 573,000 | ||||||||||||||||||
Interest | $ 4,521 | 4,521 | ||||||||||||||||||
Debt conversion, converted instrument, shares issued | 577,521 | |||||||||||||||||||
First Fire Warrant Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 53,532 | 53,532 | ||||||||||||||||||
Promissory note issued | $ 573,000 | $ 573,000 | ||||||||||||||||||
Consulting Agreement One [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 75,000 | |||||||||||||||||||
Shares issuance date | Oct. 18, 2023 | |||||||||||||||||||
Mast Hil lSecurities Warrant Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 138,703 | |||||||||||||||||||
Shares issuance date | Oct. 23, 2023 | |||||||||||||||||||
Promissory note issued | 445,000 | |||||||||||||||||||
Consulting Agreement Two [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 75,000 | |||||||||||||||||||
Shares issuance date | Nov. 08, 2023 | |||||||||||||||||||
Excutive Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 30,675 | |||||||||||||||||||
Shares issuance date | Nov. 21, 2023 | |||||||||||||||||||
Excutive Agreement One [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 18,405 | |||||||||||||||||||
Shares issuance date | Nov. 21, 2023 | |||||||||||||||||||
Warrant [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Units issued for cash, net of offering costs | 80,200 | |||||||||||||||||||
Warrants and rights outstanding term | 3 years | 3 years | ||||||||||||||||||
Proceeds of warrants | $ 80,200 | |||||||||||||||||||
Promissory note issued | $ 5,257,466 | |||||||||||||||||||
Warrant [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Promissory note issued | 77,856 | 86,327 | ||||||||||||||||||
Warrant One [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Units issued for cash, net of offering costs | 160,200 | |||||||||||||||||||
Warrants and rights outstanding term | 5 years | 5 years | ||||||||||||||||||
Proceeds of warrants | $ 160,200 | |||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Units issued for cash, net of offering costs | 400,000 | |||||||||||||||||||
Debt conversion, converted instrument, shares issued | 3,786,454 | |||||||||||||||||||
Common Stock [Member] | Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Promissory note issued | $ 74,793 | $ 82,963 | ||||||||||||||||||
Common Stock [Member] | Consulting Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Shares issuance date | Oct. 03, 2023 | |||||||||||||||||||
Common Stock [Member] | Share Exchange Agreement [Member] | ||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||
Number of restricted shares | 73,767 | |||||||||||||||||||
Shares issuance date | Oct. 09, 2023 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) | 3 Months Ended |
Nov. 30, 2023 USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | |
Other expenses | $ 652,174 |
Schedule of Segment Reporting I
Schedule of Segment Reporting Information (Details) - USD ($) | 3 Months Ended | |||
Nov. 30, 2023 | Nov. 30, 2022 | Aug. 31, 2023 | Aug. 31, 2022 | |
Segment Reporting Information [Line Items] | ||||
Sales | $ 3,891,218 | $ 3,419,280 | ||
Gross profit | 1,944,018 | 1,739,533 | ||
Income (loss) from operations | (3,317,637) | (2,241,960) | ||
Depreciation and amortization | 572,404 | 586,166 | ||
Capital expenditures | ||||
Interest expenses | 143,374 | 167,243 | ||
Net loss | (4,660,723) | (3,936,736) | ||
Total assets | 37,244,384 | $ 35,563,047 | ||
Accounts receivable | 2,636,174 | 1,467,028 | ||
Intangible assets | 15,704,218 | 16,218,539 | ||
Goodwill | 7,554,779 | 7,582,483 | $ 7,825,844 | |
Healthcare Services [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Sales | 2,044,510 | 2,021,213 | ||
Gross profit | 676,416 | 784,031 | ||
Income (loss) from operations | (80,327) | (151,691) | ||
Depreciation and amortization | 30,035 | 28,968 | ||
Capital expenditures | ||||
Interest expenses | 20,532 | 36,303 | ||
Net loss | (98,640) | (185,713) | ||
Total assets | 5,002,855 | 5,158,851 | ||
Accounts receivable | 672,841 | 697,440 | ||
Intangible assets | 111,172 | 120,163 | ||
Goodwill | 518,918 | 520,821 | ||
Product Manufacturing and Development [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Sales | 1,768,458 | 790,478 | ||
Gross profit | 1,189,352 | 347,914 | ||
Income (loss) from operations | 108,702 | (554,842) | ||
Depreciation and amortization | 262,927 | 309,042 | ||
Capital expenditures | ||||
Interest expenses | 462 | 2,464 | ||
Net loss | 48,883 | (578,576) | ||
Corporate Segment [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Sales | 78,250 | 607,589 | ||
Gross profit | 78,250 | 607,588 | ||
Income (loss) from operations | (3,346,012) | (1,535,427) | ||
Depreciation and amortization | 279,442 | 248,156 | ||
Capital expenditures | ||||
Interest expenses | 122,380 | 128,476 | ||
Net loss | (4,610,966) | $ (3,172,447) | ||
Total assets | 13,493,054 | 12,410,544 | ||
Accounts receivable | 94,946 | 4,200 | ||
Intangible assets | 12,000,621 | 12,280,063 | ||
Goodwill | ||||
Product Sales [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total assets | 18,748,475 | 17,993,652 | ||
Accounts receivable | 1,868,387 | 765,388 | ||
Intangible assets | 3,592,425 | 3,818,313 | ||
Goodwill | $ 7,035,861 | $ 7,061,662 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||||||||||||
Jan. 16, 2024 | Dec. 21, 2023 | Dec. 18, 2023 | Dec. 12, 2023 | Nov. 21, 2023 | Nov. 07, 2023 | Sep. 12, 2023 | Jun. 20, 2023 | Nov. 30, 2023 | Nov. 30, 2022 | Aug. 31, 2023 | Sep. 18, 2023 | Feb. 23, 2023 | Nov. 17, 2021 | |
Subsequent Event [Line Items] | ||||||||||||||
Debt face amount | $ 1,875,000 | |||||||||||||
Debt conversion, converted instrument, shares issued | 27,973 | |||||||||||||
Debt conversion, rate | $ 0.001 | $ 0.001 | ||||||||||||
Promissory note paid in full | $ 183,100 | |||||||||||||
Common Stock [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt conversion, converted instrument, shares issued | 3,786,454 | |||||||||||||
Units issued for cash, net of offering costs, shares | 400,000 | |||||||||||||
Subsequent Event [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Amount of debt converted | $ 454,071 | |||||||||||||
Debt conversion, converted instrument, shares issued | 457,128 | |||||||||||||
Debt conversion, rate | $ 0.99331 | |||||||||||||
Promissory note paid in full | $ 445,000 | |||||||||||||
Shares issued, price per share | $ 0.78 | |||||||||||||
Subsequent Event [Member] | Common Stock [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Units issued for cash, net of offering costs, shares | 200,000 | |||||||||||||
Ophir Agreement [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Security deposit | $ 25,000 | |||||||||||||
Repayments of related party | 60,000,000 | |||||||||||||
Repayments of related party excluding deposit | $ 59,975,000 | |||||||||||||
Mast Hill Securities Purchase Agreement [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt face amount | $ 445,000 | $ 3,500,000 | $ 445,000 | $ 573,000 | ||||||||||
Debt conversion, converted instrument, shares issued | 522,777 | |||||||||||||
Units issued for cash, net of offering costs, shares | 1,772,045 | 74,167 | ||||||||||||
Mast Hill Securities Purchase Agreement [Member] | Common Stock [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt face amount | $ 74,793 | $ 82,963 | ||||||||||||
Mast Hill Securities Purchase Agreement [Member] | Subsequent Event [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Convertible notes interest | $ 104,712 | |||||||||||||
FirstFire Securities Purchase Agreement [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt face amount | $ 277,778 | |||||||||||||
Units issued for cash, net of offering costs, shares | 480,156 | |||||||||||||
FirstFire Securities Purchase Agreement [Member] | Subsequent Event [Member] | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Convertible notes interest | $ 8,333 |